Four points of business of location
Many life science companies are located in Osaka, including world leading universities and research institutes. By fully leveraging these strengths, we are working on making innovations for the world by promoting various seamless initiatives from R & D to commercialization.
1. Superior environment for the entire cycle from R&D to industrialization
It is an optimal environment for information gathering, collaborative research, new customer development and business matching, networking with domestic and overseas companies and research institutions.
○Major universities and research institutions related to life science field
○Consolidated presence of pharmaceutical companies
2. Convenient transportation access
3.The situation of the life science industry of Osaka to know by data.
○ Regional composition of bio and equipment industry
○ Shipment amount of pharmaceuticals
○ Number of research projects for practical use of regenerative medicine
4.State-of-the-art research programs leading the world
We introduce about main example.
Immunology is one of the areas where Japan has led the world.
At the Osaka University Immunology Frontier Research Center,we are working on the cutting edge research projects centering on the world-class researchers.
Among them, Actemra (a medicine for suppressing inflammation such as rheumatoid arthritis and Castleman's disease) is a groundbreaking development across the world.
For regenerative medicine, with the introduction of “Conditional and temporary approval system” through the revision of the Pharmaceutical Affairs Law in 2014, Japan created the world leading environment.
In Kansai, we conduct advanced research with Kyoto University, RIKEN and Osaka University as the top class institutions of Japan.
Especially, Osaka is very strong in clinical research, which is close to practical use and industrialization and which is mainly conducted by Osaka University Hospital. “Heart sheet”, which is a regenerative medicine product for the treatment of heart failure jointly developed by Osaka University and Terumo Corporation was the first drug of its kind to obtain approval for manufacturing and sales. In addition, it was included in the insurance coverage in January 2016. Subsequently, it also aims to industrialize myocardium sheets using iPS cells within few years.